rofecoxib has been researched along with Patency of the Ductus Arteriosus in 1 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "To find a better treatment for patent ductus arteriosus (PDA) in premature infants, the present study investigated the synergism of clinical doses of dexamethasone, indomethacin, and rofecoxib, a selective cyclooxygenase-2 (COX-2) inhibitor, on the fetal ductus arteriosus (DA) in rats." | 1.33 | Increased constriction of the ductus arteriosus by dexamethasone, indomethacin, and rofecoxib in fetal rats. ( Imamura, S; Momma, K; Takami, T, 2005) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Takami, T | 1 |
| Momma, K | 1 |
| Imamura, S | 1 |
1 other study available for rofecoxib and Patency of the Ductus Arteriosus
| Article | Year |
|---|---|
Increased constriction of the ductus arteriosus by dexamethasone, indomethacin, and rofecoxib in fetal rats.
Topics: Animals; Anti-Inflammatory Agents; Dexamethasone; Drug Evaluation, Preclinical; Drug Therapy, Combin | 2005 |